Biogen Response to NICE Spinraza Announcement

Biogen have issued a press release following yesterdays disappointing announcement by NICE (National Institute for Health and Care Excellence), recommending that Spinraza/nusinersen not be funded, on the NHS.

Their response acknowledges the difficulties for rare disease treatment approval, within the current assessment criteria used by NICE and demonstrates a commitment to working with both NICE and NHS England to progress talks to put in place a Managed Access Agreement, so Spinraza can be made available to those who may benefit.

There will now be a consultation period, through until 5:00pm on 5th September, where feedback to the consultation document can be given here.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.